Mesoblast (MESO) FCF Payout Ratio Growth (1y) (2017 - 2023)
Mesoblast (MESO) FCF Payout Ratio Growth (1y) (2017 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 68.88% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -31.89% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -0.64% |
| Dec 31, 2022 | -6.19% |
| Sep 30, 2022 | 6.07% |
| Jun 30, 2022 | 3.89% |
| Mar 31, 2022 | 135.33% |
| Dec 31, 2021 | 15.79% |
| Sep 30, 2021 | -65.98% |
| Jun 30, 2021 | 122.25% |
| Mar 31, 2021 | -408.58% |
| Dec 31, 2020 | 102.84% |
| Sep 30, 2020 | -72.93% |
| Jun 30, 2020 | -585.68% |
| Mar 31, 2020 | 241.34% |
| Dec 31, 2019 | -426.41% |
| Sep 30, 2019 | 21.32% |
| Jun 30, 2019 | -3.05% |
| Mar 31, 2019 | 150.52% |
| Dec 31, 2018 | 930.48% |
| Sep 30, 2018 | 8.75% |
| Jun 30, 2018 | 8.21% |